FORM 51-102F3 MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

Chemesis International Inc.
Suite 2710, 200 Granville Street,
Vancouver, British Columbia V6C 1S4

Item 2 Date of Material Change

December 9, 2019

Item 3 News Release

A news release announcing the material change referred to in this report was disseminated on December 9, 2019 and subsequently filed on SEDAR at www.sedar.com.

Item 4 Summary of Material Change

On December 9, 2019, Chemesis International Inc. ("Chemesis" or the "Company") announced, further to a news release dated November 1, 2019, that certain of the cannabis licenses ("Licenses") held by its subsidiary, Natural Ventures PR, LLC ("Natural Ventures"), remain subject to the administrative review ("Review") being undertaken by the Puerto Rico Department of Health. The Company has now taken the step of instructing its Puerto Rico legal team to apply to the Puerto Rico Superior Court, San Juan, for an order establishing that the Puerto Rico Department of Health's actions in regard to the Review are not consistent with the legal and regulatory framework applicable to the Licenses.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

On December 9, 2019, the Company announced, further to a news release dated November 1, 2019, that certain of the Licenses held by its subsidiary, Natural Ventures, remain subject to the Review being undertaken by the Puerto Rico Department of Health, and that the Company has now taken the step of instructing its Puerto Rico legal team to apply to the Puerto Rico Superior Court, San Juan, for an order establishing that the Puerto Rico Department of Health's actions in regard to the Review are not consistent with the legal and regulatory framework applicable to the Licenses.

The Licenses effectively remain in abeyance, as Natural Ventures is not permitted to carry out any licensed activities under the Licenses, though Natural Ventures is permitted to carry out certain activities for the purposes of preserving and maintaining inventory.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7 <u>Omitted Information</u>

No significant facts have been omitted from this report.

Item 8 <u>Executive Officer</u>

Eli Dusenbury, Chief Financial Officer Telephone: 604-398-3378

Item 9 <u>Date of Report</u>

December 13, 2019